Tuesday, January 26, 2021 12:39:31 PM
Some items regarding Avatar:
Expect Avatar completion dates to be accurate, as these were the only Avatar record items updated at the last update (end of November).
OK, if given that completion dates are accurate, then what does that mean in terms of schedule?
It was curious that the Avatar enrollment status was not updated on the Dec 28 CC, as this trial was the one next up to have full enrollment and complete. Yet the AD trial enrollment, was updated, and it will not complete for a year. Why?
Working back from Jan31 Primary Completion (last patient, last data collected) 7 weeks, would put the last patient enrolled/accepted at Dec.7...12 days after the record update. Interesting..12 days schedule 'padding' or just coincidence?
On Dec28, the enrollment should have been complete, for trial Primary completion to end Jan31.
Dr.M just keeping the cards very close to his vest?
Almost end of January and no word of FDA meeting date. Is Dr.M waiting for the Avatar high dose data, so he can have both high and low for the meeting?
Ana estimates 33 patient results will take all of February.
March+ could be very interesting! We will be there soon!
ANAVEX2-73 Study in Patients With Rett Syndrome (AVATAR)
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : February 28, 2021
Expect Avatar completion dates to be accurate, as these were the only Avatar record items updated at the last update (end of November).
OK, if given that completion dates are accurate, then what does that mean in terms of schedule?
It was curious that the Avatar enrollment status was not updated on the Dec 28 CC, as this trial was the one next up to have full enrollment and complete. Yet the AD trial enrollment, was updated, and it will not complete for a year. Why?
Working back from Jan31 Primary Completion (last patient, last data collected) 7 weeks, would put the last patient enrolled/accepted at Dec.7...12 days after the record update. Interesting..12 days schedule 'padding' or just coincidence?
On Dec28, the enrollment should have been complete, for trial Primary completion to end Jan31.
Dr.M just keeping the cards very close to his vest?
Almost end of January and no word of FDA meeting date. Is Dr.M waiting for the Avatar high dose data, so he can have both high and low for the meeting?
Ana estimates 33 patient results will take all of February.
March+ could be very interesting! We will be there soon!
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
